Abstract
Purpose: To investigate whether multiphasic MDCT enhancement can help differentiate type 1 papillary renal cell carcinoma (RCC) from type 2 papillary RCC. Methods: With IRB approval for this HIPAA-compliant retrospective study, we derived a cohort of 36 type 1 papillary RCCs and 33 type 2 papillary RCCs with preoperative multiphasic MDCT with up to four phases (unenhanced, corticomedullary, nephrographic, and excretory) from 2000 to 2013. Following segmentation, a computer-assisted detection (CAD) algorithm selected a 0.5 cm-diameter region of maximal attenuation within each lesion in each phase; a 0.5 cm-diameter region of interest was manually placed on uninvolved renal cortex in each phase. The relative attenuation of each lesion was calculated as [(Lesion attenuation−cortex attenuation)/cortex attenuation] × 100. Absolute and relative attenuation values were compared using Mann–Whitney tests with Bonferroni correction for multiple comparisons. Results: Relative excretory phase attenuation of type 2 papillary RCCs was significantly greater than that of type 1 papillary RCCs (2.0 vs. −18.3, p = 0.005). Relative excretory phase attenuation differentiated type 1 papillary RCCs from type 2 papillary RCCs with an accuracy of 73% (36/49), sensitivity of 87% (26/30), positive predictive value of 74% (26/35), and negative predictive value of 71% (10/14). Conclusion: Multiphasic MDCT enhancement may assist in differentiating type 1 papillary RCCs from type 2 papillary RCCs, if prospectively validated.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1911-1918 |
| Number of pages | 8 |
| Journal | Abdominal Radiology |
| Volume | 42 |
| Issue number | 7 |
| DOIs | |
| State | Published - Jul 1 2017 |
| Externally published | Yes |
Fingerprint
Keywords
- Multidetector computed tomography
- Renal cell carcinoma
- Type 1 papillary renal cell carcinoma
- Type 2 papillary renal cell carcinoma
ASJC Scopus subject areas
- Radiological and Ultrasound Technology
- Radiology Nuclear Medicine and imaging
- Gastroenterology
- Urology
Cite this
Type 1 papillary renal cell carcinoma : differentiation from Type 2 papillary RCC on multiphasic MDCT. / Young, Jonathan R; Coy, Heidi; Douek, Michael; Lo, Pechin; Sayre, James; Pantuck, Allan J.; Raman, Steven S.
In: Abdominal Radiology, Vol. 42, No. 7, 01.07.2017, p. 1911-1918.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Type 1 papillary renal cell carcinoma
T2 - differentiation from Type 2 papillary RCC on multiphasic MDCT
AU - Young, Jonathan R
AU - Coy, Heidi
AU - Douek, Michael
AU - Lo, Pechin
AU - Sayre, James
AU - Pantuck, Allan J.
AU - Raman, Steven S.
PY - 2017/7/1
Y1 - 2017/7/1
N2 - Purpose: To investigate whether multiphasic MDCT enhancement can help differentiate type 1 papillary renal cell carcinoma (RCC) from type 2 papillary RCC. Methods: With IRB approval for this HIPAA-compliant retrospective study, we derived a cohort of 36 type 1 papillary RCCs and 33 type 2 papillary RCCs with preoperative multiphasic MDCT with up to four phases (unenhanced, corticomedullary, nephrographic, and excretory) from 2000 to 2013. Following segmentation, a computer-assisted detection (CAD) algorithm selected a 0.5 cm-diameter region of maximal attenuation within each lesion in each phase; a 0.5 cm-diameter region of interest was manually placed on uninvolved renal cortex in each phase. The relative attenuation of each lesion was calculated as [(Lesion attenuation−cortex attenuation)/cortex attenuation] × 100. Absolute and relative attenuation values were compared using Mann–Whitney tests with Bonferroni correction for multiple comparisons. Results: Relative excretory phase attenuation of type 2 papillary RCCs was significantly greater than that of type 1 papillary RCCs (2.0 vs. −18.3, p = 0.005). Relative excretory phase attenuation differentiated type 1 papillary RCCs from type 2 papillary RCCs with an accuracy of 73% (36/49), sensitivity of 87% (26/30), positive predictive value of 74% (26/35), and negative predictive value of 71% (10/14). Conclusion: Multiphasic MDCT enhancement may assist in differentiating type 1 papillary RCCs from type 2 papillary RCCs, if prospectively validated.
AB - Purpose: To investigate whether multiphasic MDCT enhancement can help differentiate type 1 papillary renal cell carcinoma (RCC) from type 2 papillary RCC. Methods: With IRB approval for this HIPAA-compliant retrospective study, we derived a cohort of 36 type 1 papillary RCCs and 33 type 2 papillary RCCs with preoperative multiphasic MDCT with up to four phases (unenhanced, corticomedullary, nephrographic, and excretory) from 2000 to 2013. Following segmentation, a computer-assisted detection (CAD) algorithm selected a 0.5 cm-diameter region of maximal attenuation within each lesion in each phase; a 0.5 cm-diameter region of interest was manually placed on uninvolved renal cortex in each phase. The relative attenuation of each lesion was calculated as [(Lesion attenuation−cortex attenuation)/cortex attenuation] × 100. Absolute and relative attenuation values were compared using Mann–Whitney tests with Bonferroni correction for multiple comparisons. Results: Relative excretory phase attenuation of type 2 papillary RCCs was significantly greater than that of type 1 papillary RCCs (2.0 vs. −18.3, p = 0.005). Relative excretory phase attenuation differentiated type 1 papillary RCCs from type 2 papillary RCCs with an accuracy of 73% (36/49), sensitivity of 87% (26/30), positive predictive value of 74% (26/35), and negative predictive value of 71% (10/14). Conclusion: Multiphasic MDCT enhancement may assist in differentiating type 1 papillary RCCs from type 2 papillary RCCs, if prospectively validated.
KW - Multidetector computed tomography
KW - Renal cell carcinoma
KW - Type 1 papillary renal cell carcinoma
KW - Type 2 papillary renal cell carcinoma
UR - http://www.scopus.com/inward/record.url?scp=85014531180&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85014531180&partnerID=8YFLogxK
U2 - 10.1007/s00261-017-1091-x
DO - 10.1007/s00261-017-1091-x
M3 - Article
C2 - 28265706
AN - SCOPUS:85014531180
VL - 42
SP - 1911
EP - 1918
JO - Abdominal Radiology
JF - Abdominal Radiology
SN - 2366-004X
IS - 7
ER -